Schedule 13G ownership disclosure
INOZYME PHARMA INC
Common Stock · CUSIP: 45790W108
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Beryl Capital Management LLC
Shares: 0.00 · Class: 0%
- Beryl Capital Management LP
Shares: 0.00 · Class: 0%
- Beryl Capital Partners II LP
Shares: 0.00 · Class: 0%
- David A. Witkin
Shares: 0.00 · Class: 0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000935836-25-000513
- Form type
- SCHEDULE 13G/A
- Filer
- Beryl Capital Management LLC
- CIK
- CIK 1719307
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership